The in vitro activity of HR 756, a new cephalosporin, has been determined against recent clinical isolates and compared with that of other j3-lactam antibiotics.
cephalosporanic acid, is a cephalosporin compound which is highly active against both Gram-negative rods and Gram-positive cocci."3'" Its activity was compared with that of cephalothin, cefazolin, cefuroxime and cefoxitin, and carbenicillin, and azlocillin, a new ureido-penicillin2'. All strains were of human origin, isolated and identified in our laboratory. HR 756 was supplied by Hoechst AG, cephalothin by E. Lilly, cefazolin by Boehringer Mannheim, cefuroxime by Glaxo/Hoechst AG and cefoxitin by Merck, Sharp & Dohme.
Azlocillin and carbenicillin were obtained from Bayer AG.
Stock antibiotic solutions were prepared each day.
Minimum inhibitory concentrations (MIC) were determined by an agar dilution technique using D.S.T. agar (Oxoid), except for Proteus species, where KLED agar (Oxoid) was used." ' The inoculurn
size was approximately 106 colony forming units/nil (CFU/ml). A multi-point inoculator was used to inoculate the plates.
Effect of inoculum:
The effect of inoculum size on the MIC of HR 756 was determined using three different inocula: 103, 106 and 10° CFU/ml.
The tables show the geometrical means of the MIC's for different isolates. Bactericidal activity: Bactericidal activity was evaluated by the membrane filtration technique, described by KLEIN61, OBERZILLB1 and VOMEL9/ but was modified in our laboratory.7 '8 A half ml of a 102 diluted four-hour culture of the test strain was added to a flask containing 49.5 ml of the Antibiotic Medium 3 (Difco) and the appropriate concentration of the antibiotic. Colony counts were performed at 0, 30 minutes, 1, 2, 4, 8 and 24 hours. The filters (Sartorius filter, grade 0.2 µm, 50 mm diameter) were cultured on Standard I Agar (Merck) or KLED agar (for Proteus species) at 37°C for 18 -24 hours. Colony forming units surviving after exposure to HR 756 were defined in percentage of inoculum and plotted against time.
Results
The results of the in vitro susceptibility testing of isolates to HR 756 are summarized in Tables 1-' 3. HR 756 was more active than cephalothin, cefazolin, cefuroxime and cefoxitin against all Gram-negative Concentration (mcg/ml) required to inhibit given % of strains Viable counts via membrane filtration in Antibiotic Medium 3. Minimum inhibitory concentrations for all strains I mcg/ml. Table 9 . Geometrical mean of the minimum inhibitory concentration in mcg/ml (n. d. =not determined).
(n=number of isolates tested) Tables 4 -7 give the time needed to kill 99 % of the inoculum.
Against P. aeruginosa HR 756 needed more time to kill 99% of the inoculum (Table 7) . In fact against one strain HR 756 failed to kill 99 % of the inoculum. Fig. 4 shows the bactericidal effect of HR 756 at different times against S. aureus. It is obvious that the bactericidal activity against S. aureus strains is poor. Table 8 lists the geometric means of MICs at different inocula. Only with S. aureus and more markedly with P. aeruginosa was there a rise in MIC with an increase in the size of the inoculum.
Discussion
Of the cephalosporins, including the cephamycin and cefoxitin compared in this study, HR 756 was the most active compound against enterobacteriaceae. Table 9 gives the geometrical means of the MICs determined. Against S. aureus strains (both penicillin-sensitive and resistant) the geometrical mean of the MICs was <1 mcg/ml. Cephalothin and cefazolin were more active than HR 756, especially against penicillin-resistant S. aureus strains. Here, cefoxitin was the least active compound. It is noteworthy that although the MIC against S. aureus was low, HR 756 failed to bring about any marked reduction of the inoculum (Fig. 4) .
The most striking result was that HR 756 was more active against P. aeruginosa than carbenicillin on a weight basis, azlocillin being more active. HEYMES, LUTZ and SCHRINNER have reported similar results".
The activity of HR756 was affected by inoculum size only against S. aureus and P. aeruginosa , whereas increasing the inoculum from 10' to 10° CFU/ml of E. coli and K. pneumoniae did not change the MIC significantly.
The first in vitro experience against clinical isolates with this new compound is promising and our first clinical trials show HR 756 to be effective and safe. Further studies are recommended.
